Mutational Analysis in Urinary Cell-Free DNA: KRAS in Colorectal Cancer

Chiara Molinari; Elisa Chiadini

doi:10.1007/978-1-0716-1354-2_3

Mutational Analysis in Urinary Cell-Free DNA: KRAS in Colorectal Cancer

Methods Mol Biol. 2021:2292:23-33. doi: 10.1007/978-1-0716-1354-2_3.

Authors

Chiara Molinari¹, Elisa Chiadini²

Affiliations

¹ Biosciences Laboratory, IRCCS Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - IRST S.r.l., Meldola, Italy. chiara.molinari@irst.emr.it.
² Biosciences Laboratory, IRCCS Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - IRST S.r.l., Meldola, Italy.

PMID: 33651349
DOI: 10.1007/978-1-0716-1354-2_3

Abstract

Urinary cell-free DNA offers an important noninvasive source of material for genomic testing also for nonurological tumors. Its clinical utility in monitoring tumor evolution and treatment failure is promising. Here we describe a method to detect cancer mutations into urine from patients affected by colorectal cancer.

Keywords: Cancer; Monitoring; Mutation; PCR; Urinary cell-free DNA.

MeSH terms

Biomarkers, Tumor / genetics
Biomarkers, Tumor / isolation & purification
Biomarkers, Tumor / urine
Cell-Free Nucleic Acids / genetics*
Cell-Free Nucleic Acids / isolation & purification
Cell-Free Nucleic Acids / urine
Colorectal Neoplasms / genetics*
Colorectal Neoplasms / urine
DNA Mutational Analysis / methods*
Humans
Proto-Oncogene Proteins p21(ras) / genetics*
Real-Time Polymerase Chain Reaction / methods

Substances

Biomarkers, Tumor
Cell-Free Nucleic Acids
KRAS protein, human
Proto-Oncogene Proteins p21(ras)